Skip to main content
. 2022 Jul 28;12:933278. doi: 10.3389/fonc.2022.933278

Figure 3.

Figure 3

Recurrence-free survival of biopsy-proven N2 NSCLC patients who underwent upfront surgery or induction chemotherapy.